Promising trends in Alzheimers treatment March 10, 2011

The Science Committees of the German American Business Association GABA and the French American Chamber of Commerce FACCSF have invited experts from industry, research and clinical research to discuss the most promising research and trends in Alzheimer's treatment.

Alzheimer's disease is the most common form of senile dementia. It has been estimated that 35.6 million people living with dementia worldwide in 2010, requiring 604 billion US dollar for treatment on multiple levels.

The disease is typically associated with a slow but progressive loss of nerve cells and nerve cell contacts. Recent advancements in the study of Alzheimer's disease brain function in mice has determined that neural stem cells injected into the brains of those mice help to rebuild neural connections and thereby improve cognitive function. GCSF (granulocyte colony stimulating factor) has been shown to reduce levels of a brain clogging specific protein (beta amyloid), while at the same time increasing new neuron development and nerve cell connections.

Learn more about these new development from our panel of experts:
- William F. Goure, Ph.D., President & Chief Executive Officer, Acumen Pharmaceuticals, Inc.
- Dale Bredesen, Professor and Founding President, Buck Institute
- James Treanor, Director of Neuroscience, Amgen

Moderated by:
- Ulrike Ruppelt, Principal, Ticular-Strategies for Success
- Edda Kargel Mihaescu, Ph. D., P.E., Principal Engineer, Bayer HealthCare

Agenda:
6:00 - 7:00 pm Registration and Networking Reception
7:00 - 8:30 pm Program
8:30 - 9:00 pm Networking

Complimentary appetizers, beer, wine and soft drinks will be served.

Official Website: http://www.gaba-network.org